Unveiling 6 Analyst Insights On Nurix Therapeutics
Portfolio Pulse from Benzinga Insights
In the past three months, 6 analysts have rated Nurix Therapeutics (NASDAQ:NRIX) with varying perspectives. The average 12-month price target has increased by 28.82% to $33.17. Analysts have shown a positive shift in sentiment, with recent upgrades and increased price targets.
October 11, 2024 | 5:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Nurix Therapeutics has seen a positive shift in analyst sentiment, with a 28.82% increase in the average 12-month price target to $33.17. Recent analyst actions include upgrades and increased price targets, indicating a bullish outlook.
The article highlights a positive shift in analyst sentiment towards Nurix Therapeutics, with a significant increase in the average price target. Multiple analysts have upgraded their ratings and increased their price targets, suggesting a bullish outlook for the stock. This is likely to have a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100